A new treatment for pancreatic cancer has been approved by the FDA. This approval brings hope for patients with a particularly aggressive form of the disease. The medication, which will be marketed under a specific brand name, works by targeting a protein that contributes to tumor growth.

Patients who took the medication as part of a study experienced improved outcomes, with longer survival times and fewer severe side effects. The study involved a large group of patients with metastatic cancer.

Further information about this breakthrough is available, including details about the study and the medication's development.